Pricing Log in Create free account
Saturday 17 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

156.19 1.18 −0.75%
Market cap
$195.1B
P/E
0.0×
Fwd P/E
−46.2×
Dividend yield
2.08%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Gilead Sciences, Inc. (GILD) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Gilead Sciences, Inc. (GILD) trades at a EV/EBITDA of 829×. Over the past ten years it has ranged from 5.4× (December 2016) to 835× (October 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 13.3× (55.34%)
FY2024 29.8× 149.58%
FY2023 11.9× (11.50%)
FY2022 13.5× 43.63%
FY2021 9.4× (47.06%)
FY2020 17.7× 20.47%
FY2019 14.7× 78.38%
FY2018 8.3× 20.61%
FY2017 6.8× 12.05%
FY2016 6.1× (8.82%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 687× 4,708.00%
Mar 2026 14.3× 7.51%
Dec 2025 13.3× 13.33%
Sep 2025 11.7× (19.51%)
42 more quarters

Against its own ten years

Low 5.4× High 835×
Ten-year median 10.6×
Current reading's percentile 100

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
GSK GSK PLC Sponsored ADR compare 9.3×
BMY Bristol Myers Squibb Company compare 10.2×
PFE Pfizer Inc. compare 10.8×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. compare 16.8×
MRK Merck & Co., Inc. compare 29.5×
GILD Gilead Sciences, Inc. 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on GILD